Enjoy complimentary customisation on priority with our Enterprise License!
The global dementia and movement disorder treatment market size is estimated to grow by USD 8.55 billion, at a CAGR of 7.28% between 2023 and 2028.
In the global dementia and movement disorder treatment market, the risk of developing dementia increases exponentially with age, the CDC estimates that currently, approximately 200,000 people under age 65 in the US are living with younger-onset dementia, mainly Alzheimer's disease. The early onset of Alzheimer's disease symptoms is often called younger-onset dementia. The risk of the younger onset of Alzheimer's is four to five times higher in individuals with Down's syndrome. To offset the impact of younger onset among adults in the US, the US Department of Health and Human Services (HHS) created a special committee, the National Plan to Address Alzheimer's Disease, that takes care of individuals with Down's syndrome and younger-onset Alzheimer's by meeting the needs of American families currently facing these diseases. Furthermore, in addition to government initiatives, several other non-government initiatives have sprung up with individuals with younger-onset Alzheimer's, forming support networks to spread awareness about the symptoms of the disease and their unique needs. Thus, the growing efforts taken to increase public awareness regarding younger-onset dementia are anticipated to drive market growth during the forecast period.
Technavio has segmented the market into Application, Drug Class, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our market research and growth report examines historical data from 2018-2022, besides analyzing market growth and forecasting.
To learn more about this report, Download Report Sample
The market share growth by the movement disorders segment will be significant during the forecast period. Movement disorders refer to a group of neurological conditions that primarily affect a person's ability to produce and control movements. Movement disorders can significantly impact an individual's ability to perform daily activities and lead a fulfilling life. Effective medications that can manage symptoms and enhance functional abilities are in demand to improve the quality of life for those affected.
Get a glance at the market contribution of various segments Download PDF Sample
The movement disorders segment was valued at USD 10.57 billion in 2018. Pharmaceutical companies, in collaboration with researchers and healthcare providers, are actively working on developing new medications and refining existing treatments to meet the growing demand for effective drugs that address various movement disorders. Emerging discoveries about movement disorder disease mechanisms are creating demand for medications that can more effectively intervene in the disease process, which is expected to propel the growth of the global dementia and movement disorder treatment market during the forecast period.
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that block the actions of one or both MAO enzymes such as monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). MAO-B is a flavin adenine dinucleotide (FAD)-dependent mitochondrial enzyme. It is one of the two subtypes of the major monoamine metabolizing enzyme that regulates the levels of several chemicals in the brain, including the neurotransmitter dopamine. In addition, the literature on MAO-A inhibition in Parkinson's disease is comparatively scarce. However, various studies are being conducted to determine the role of this enzyme as a part of the therapeutic treatment of Parkinson's disease. Besides, MAO-B inhibitors such as selegiline, rasagiline, and safinamide are used to manage the early symptoms of the disease. Thus, the rising prevalence of Parkinson's disease and related disorders is expected to lead to an increase in the consumption of MAO inhibitors, thus driving market growth during the forecast period.
AChE is a hydrolytic enzyme that terminates acetylcholine (ACh)-mediated signal transmission by breaking down ACh in cholinergic synapses of the brain. ACh is a neurotransmitter that helps in the transmission of signals across nerve synapses. It is synthesized in nerve terminals and stored in vesicles. On receiving nerve impulses, nerve cells release ACh from vesicles, which reach the synaptic cleft and innervate postsynaptic and presynaptic receptors. The progressive death of cholinergic brain cells leads to dysfunction of cholinergic signal transmission and impairs the memory and behavior of a person, leading to Alzheimer's disease. In addition, AChE has been reported to be associated with senile plaques and other hallmarks of Alzheimer's disease. Thus, maintenance of adequate levels of choline by inhibiting AChE is a viable treatment approach for the management of the disease. AChE inhibitors act by inhibiting AChE in a competitive or non-competitive manner. Thus, such studies are expected to have a favorable impact on the growth of the global dementia and movement disorder treatment market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America dominated the global dementia and movement disorder treatment market, with the US and Canada being significant revenue contributors to the market. The presence of global key market players in the US is driving the market growth. Furthermore, factors such as the advanced healthcare system and the patient-assistance programs by the Patient Access Network (PAN) Foundation in the US are expected to drive market growth in the region during the forecast period. Additionally, Increasing investments will bring about substantial growth opportunities in the market. Thus, the rise in government interest in drug development for dementia and movement disorders is expected to drive market growth in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AbbVie Inc.: The company offers treatment for dementia and movement disorder under the brand names of Namenda and Duopa, where the initial dosage is 5 mg once daily and are available in the form of tablets of 5 mg and 10 mg.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
The rising prevalence of target diseases is the key factor driving market growth. According to WHO, in September 2021, more than 55 million people were affected by dementia worldwide, and nearly 10 million new cases are diagnosed every year globally. In addition, as per WHO, Alzheimer's disease is one of the most common forms of dementia and accounts for 60%-70% of the cases. The disease is prevalent in people aged 65 years or above, and women are more susceptible to it than men. Neuronal loss associated with Alzheimer's disease reduces brain size and results in the deposition of debris from the dead and dying neurons in the brain.
Furthermore, some other types of dementia include Parkinson's disease, Lewy body dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, Huntington's disease, Wernicke-Korsakoff syndrome, and Binswanger's disease. Consequently, the high requirement for the treatment of different types of dementia will propel the demand for treatment drugs, thereby driving the growth of the global dementia and movement disorder treatment market during the forecast period.
Advances in biomedical science is the primary trend shaping market growth. Modern techniques like bioinformatics, molecular targeting, nanotechnology, and personalized medicine facilitated drug development in the area of neurodegenerative disorders, including dementia. Bioinformatics employs the use of a mathematical model to enhance the understanding of human systems. The currently available neuroimaging and cerebrospinal fluid-based diagnoses used for detecting Alzheimer's disease are costly. Therefore, bioinformatics is being used to improve the diagnosis of Alzheimer's disease.
Additionally, the availability of enhanced biotechnological tools such as ribonucleic acid interference (RNAi) and a better understanding of the human genome has led to the development of targeted therapies for patients. Besides, ongoing research trials utilizing these modern technologies underscore the positive impact of biomedical science advances on the global dementia and movement disorder treatment market in the forecast period, aligning with current market trends and analysis.
Failure rates of drugs in clinical trials is a challenge that affects market growth. The development of dementia therapeutics and their clinical trials remain vulnerable to challenges, which further hinder the development of curative therapies for the treatment of dementia. There are currently four drugs that are approved and being used for the symptomatic treatment of Alzheimer's disease, which include donepezil, rivastigmine, galantamine, and memantine. However, several drugs identified as potential therapies for Alzheimer's disease failed in clinical trials.
Additionally, failure in clinical trials often leads to discontinuation of drugs and, therefore, wastage of revenue spent on the initial development of the drug. Failure in clinical trials can also lead to the termination of strategic industry partnerships, which are otherwise essential to boost R&D activities in the market. Hence, such factors are likely to hinder the growth of the global dementia and movement disorder treatment market during the forecast period.
The market report includes the adoption lifecycle of the market forecast, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market analysis and report also include key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Dementia and Movement Disorder Treatment Market Customer Landscape
The dementia and movement disorder treatment market report forecasts market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends from 2018 to 2028.
Dementia and Movement Disorder Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
177 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.28% |
Market Growth 2024-2028 |
USD 8.55 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
6.63 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 47% |
Key countries |
US, Canada, Germany, UK, and France |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kirin Holdings Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and UCB SA |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.